Evidence map›Paper›PMID 40302099›Full record

ArticleAsian Pacific journal of cancer prevention : APJCP2025

Correlation between Isocitrate Dehydrogenase Mutation and Immunohistochemical Expression of DNA Mismatch Repair Proteins in the Prognosis of Gliomas.

Nelly Mohamed Saeed, Hayam Rashed, Samia Hussein, Amira S Al-Karamany, Wael Elmesallamy, Ahmad Barakat Waley, Ahmed Ali Obaya, Shimaa A Gharieb, Kareem Amgd, Sara Mohammed Ibrahim and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Asian Pacific journal of cancer prevention : APJCP, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Nelly Mohamed SaeedDepartment of Pathology, Faculty of Medicine, Zagazig University, Egypt.
Hayam RashedDepartment of Pathology, Faculty of Medicine, Zagazig University, Egypt.
Samia HusseinDepartment of Medical Biochemistry and Molecular Biology, Faculty of Medicine, Zagazig University, Egypt.
Amira S Al-KaramanyDepartment of Medical Biochemistry and Molecular Biology, Faculty of Medicine, Zagazig University, Egypt.
Wael ElmesallamyDepartment of Neurosurgery, Faculty of Medicine, Zagazig University, Egypt.
Ahmad Barakat WaleyDepartment of Medical Oncology, Faculty of Medicine, Zagazig University, Egypt.
Ahmed Ali ObayaDepartment of Clinical Oncology and Nuclear Medicine, Faculty of Medicine, Zagazig University, Egypt.
Shimaa A GhariebDepartment of Clinical Oncology and Nuclear Medicine, Faculty of Medicine, Zagazig University, Egypt.
Kareem AmgdFaculty of Medicine, Zagazig University, Egypt.
Sara Mohammed IbrahimDepartment of Clinical Pathology, Faculty of Medicine, Zagazig University, Egypt.
Mohamed I AbdelhamidDepartment of Surgery, Faculty of Medicine, Zagazig University, Egypt.
Tarek KhamisDepartment of Pharmacology, Faculty of Veterinary Medicine, Zagazig University, Egypt.
Asmaa Hussein MohamedDepartment of Pathology, Faculty of Medicine, Zagazig University, Egypt.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundGliomas comprise about a third of all brain tumors and 80% of malignant brain cancers. Isocitrate dehydrogenase (IDH) normally converts isocitrate to α-ketoglutarate (α-KG), but mutant IDH gives an oncometabolite, 2-hydroxyglutarate (2-HG) that inhibits α-KG-dependent dioxygenases and inhibits cellular differentiation.

objectivesThis work aims to study the mutation in the IDH1 gene and the expression of mismatch repair (MMR) proteins in gliomas and to study the relationship between IDH1 mutation and MMR expression and the prognosis of gliomas.

methodsThis study included 60 patients with gliomas. Brain tissues were used for DNA extraction with subsequent mutation analysis. Paraffin blocks of brain tissues were prepared for routine histopathological examination and immunohistochemical examination of MMR proteins.

resultsIDH1 mutation and MLH1 and MSH2 expressions were not statistically associated with any of the studied patient or tumor characteristics. No statistically significant association was observed between MSH6 expression in the studied patients and tumor characteristics. No significant association was detected between IHC expression for MLH1, MSH6, MSH2 expression, and IDH1 mutation. No significant association was determined between the expression of MSH6 and IDH1 mutation, or MLH1 expression. A significant association was determined between MSH2 and MSH6 expression. There was a significant association between IDH1 mutation, MSH6, and MSH2 expressions and glioma progression-free survival (PFS). Log Rank test showed that mutant IDH1 and MSH6 expressions had a favorable prognosis.

conclusionIDH1 mutation and MMR proteins (MLH1, MSH6, and MSH2) could help predict glioma outcome.

Indexed as

Biomarkers, TumorBrain NeoplasmsDNA-Binding ProteinsDNA Mismatch RepairGliomaIsocitrate DehydrogenaseMutationAdultAgedFemaleFollow-Up StudiesHumansImmunohistochemistryMaleMiddle AgedMutL Protein Homolog 1Biomarkers, TumorDNA-Binding ProteinsG-T mismatch-binding proteinIDH1 protein, humanIsocitrate DehydrogenaseMLH1 protein, humanMSH2 protein, humanMutL Protein Homolog 1MutS Homolog 2 Proteingliomasisocitrate dehydrogenase mutationmismatch repair proteins

Identifiers

PMID40302099
PMCPMC12227986

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.